Skin Conditions & Dermatology Clinical Trials Update: Week 18, 2026
Published May 1, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This Phase 3 study is comparing two treatments for children aged 2 to under 12 who have moderate to severe atopic dermatitis, which causes rash and itching. The trial tests oral upadacitinib against injectable dupilumab to see which is safer and more effective. Results from this global study, which follows about 675 children for over three years, could lead to better daily care options for young patients.
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial is focused on adolescents with moderate-to-severe atopic dermatitis, evaluating a new injectable treatment called SHR-1819. Conducted in China with around 200 participants, it aims to improve skin symptoms and quality of life for teens. If successful, this treatment could offer a fresh option for managing this challenging skin condition.
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Children aged 6 to 12 with severe alopecia areata, a condition that causes hair loss, may benefit from this trial testing ritlecitinib, an oral medication. The study is recruiting in multiple countries and will track hair regrowth and safety over six months. Positive results could provide an easier-to-take treatment to help children regain hair and confidence.
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This Phase 3 trial is testing abrocitinib, an oral drug for children aged 6 to under 12 with moderate-to-severe eczema. The study is happening in several countries and aims to see if this medicine can reduce symptoms more easily than current treatments. Findings expected after 16 weeks could lead to a new option for managing eczema in kids.
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study looks at two dosing plans of amlitelimab, an injectable medicine for people aged 12 and up with moderate-to-severe atopic dermatitis. It compares continued treatment against stopping the medicine to understand how well it maintains skin improvements. Results from this trial, which is not recruiting but active, will offer insight into long-term management of this condition.
This week saw important progress in trials testing new treatments for children and adolescents with atopic dermatitis, eczema, and alopecia areata. These efforts reflect ongoing work to find safer, easier-to-use, and more effective options to improve skin health and quality of life for young patients. As these studies advance, patients and caregivers can look forward to more personalized and accessible care possibilities in the near future.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.